Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients

Clinical and Experimental Immunology

Volumn 178, Issue 1, 2014, Pages 40-47

  Westra, J ^a   Van Assen, S ^b   Wilting, K R ^c   Land, J ^a   Horst, G ^a   de Haan, A ^c   Bijl, M ^d  

^a Department of Rheumatology and Clinical Immunology ^*  (Netherlands)

^b Division of Infectious Diseases   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d MARTINI HOSPITAL   (Netherlands)

Author keywords

IgG antibodies; IgM antibodies; Influenza; Rheumatoid arthritis; Rituximab

Indexed keywords

B CELL ACTIVATING FACTOR; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INFLUENZA VACCINE; RITUXIMAB; VIRUS ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHOTREXATE; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; MALE; RHEUMATOID ARTHRITIS; SEASONAL INFLUENZA; TREATMENT RESPONSE; ARTHRITIS, RHEUMATOID; IMMUNOLOGY; INFLUENZA; MIDDLE AGED; PROCEDURES; VACCINATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODIES, VIRAL; ARTHRITIS, RHEUMATOID; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; METHOTREXATE; MIDDLE AGED; VACCINATION;

EID: 84908213385     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12390     Document Type: Article

References (31)

1. Atzeni F, Bendtzen K, Bobbio-Pallavicini F et al. Infections and treatment of patients with rheumatic diseases. Clin Exp Rheumatol 2008; 26 (1 Suppl. 48):S67-73.
2. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010; 39:327-46.
3. Galloway JB, Hyrich KL, Mercer LK et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment:updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxf) 2011; 50:124-31.
4. Lane MA, McDonald JR, Zeringue AL et al. TNF-alpha antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis. Medicine (Balt) 2011; 90:139-45.
5. Grijalva CG, Kaltenbach L, Arbogast PG, Mitchel EF Jr, Griffin MR. Initiation of rheumatoid arthritis treatments and the risk of serious infections. Rheumatology (Oxf) 2010; 49:82-90.
6. Zambon MC. Epidemiology and pathogenesis of influenza. J Antimicrob Chemother 1999; 44 (Suppl. B):3-9.
7. Chalmers A, Scheifele D, Patterson C et al. Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Rheumatol 1994; 21:1203-6.
8. Del Porto F, Lagana B, Biselli R et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity. Vaccine 2006; 24:3217-23.
9. Elkayam O. Safety and efficacy of vaccination against influenza in patients with rheumatoid arthritis. Clin Dev Immunol 2006; 13:349-51.
10. Fomin I, Caspi D, Levy V et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 2006; 65:191-4.
11. Oren S, Mandelboim M, Braun-Moscovici Y et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis 2008; 67:937-41.
12. van Assen S, Holvast A, Benne CA et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010; 62:75-81.
13. Xanthouli P, Sailer S, Fiehn C. Rituximab (RTX) as an alternative to TNF-alpha antagonists in patients with rheumatoid arthritis and high risk of severe infections: a systematic analysis of the experience in one center. Open Rheumatol J 2012; 6:286-9.
14. Arad U, Tzadok S, Amir S et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine 2011; 29:1643-8.
15. de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 2003; 115:63-73.
16. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment:relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006; 54:723-32.
17. Bombardieri M, Kam NW, Brentano F et al. A BAFF/APRILdependent TLR3-stimulated pathway enhances the capacity of rheumatoid synovial fibroblasts to induce AID expression and Ig class-switching in B cells. Ann Rheum Dis 2011; 70:1857-65.
18. Chen L, Ran MJ, Shan XX et al. BAFF enhances B-cell-mediated immune response and vaccine-protection against a very virulent IBDV in chickens. Vaccine 2009; 27:1393-9.
19. Arnett FC, Edworthy SM, Bloch DA et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
20. Holvast A, Huckriede A, Wilschut J et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis 2006; 65:913-8.
21. van Assen S, Elkayam O, Agmon-Levin N et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European league against rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun Rev 2011; 10:341-52.
22. Rehnberg M, Brisslert M, Amu S, Zendjanchi K, Hawi G, Bokarewa MI. Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment. Arthritis Res Ther 2010; 12:R111.
23. Pescovitz MD, Torgerson TR, Ochs HD et al. Effect of rituximab on human in vivo antibody immune responses. J Allergy Clin Immunol 2011; 128:1295-302.
24. Stepanova L, Naykhin A, Kolmskog C et al. The humoral response to live and inactivated influenza vaccines administered alone and in combination to young adults and elderly. J Clin Virol 2002; 24:193-201.
25. El-Madhun AS, Cox RJ, Haaheim LR. The effect of age and natural priming on the IgG and IgA subclass responses after parenteral influenza vaccination. J Infect Dis 1999; 180:1356-60.
26. Ritterhouse LL, Crowe SR, Niewold TB et al. B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels. Arthritis Rheum 2011; 63:3931-41.
27. Elgueta R, de Vries VC, Noelle RJ. The immortality of humoral immunity. Immunol Rev 2010; 236:139-50.
28. Anar C, Bicmen C, Yapicioglu S, Unsal I, Halilcolar H, Yilmaz U. Evaluation of clinical data and antibody response following influenza vaccination in patients with chronic obstructive pulmonary disease. New Microbiol 2010; 33:117-27.
29. Arankalle VA, Virkar RG, Tandale BV, Ingle NB. Utility of pandemic H1N1 2009 influenza virus recombinant hemagglutinin protein-based enzyme-linked immunosorbent assay for serosurveillance. Clin Vaccine Immunol 2010; 17:1481-3.
30. Comin A, Toft N, Stegeman A, Klinkenberg D, Marangon S. Serological diagnosis of avian influenza in poultry: is the haemagglutination inhibition test really the 'gold standard'? Influenza Other Respir Viruses 2013; 7:257-64.
31. Bodle J, Verity EE, Ong C et al. Development of an enzyme-linked immunoassay for the quantitation of influenza haemagglutinin:an alternative method to single radial immunodiffusion. Influenza Other Respir Viruses 2013; 7:191-200.